Regen BioPharma Inc (RGBP)

[PennyPusher786]

Regen BioPharma Inc

About the company

Regen BioPharma Inc. is a publicly traded biotechnology company (OTCQB: RGBP) and (OTCQB: RGBPP)  focused on the immunology and immunotherapy space. The Company plans to rapidly advance novel technologies through pre-clinical and Phase I/ II clinical trials. Currently, the Company is advancing small molecule therapies for treating cancer and autoimmune disorders by modulating the Checkpoint NR2F6.  The company also developing products treating blood disorders using small molecules and gene silencing (DiffronC), treating cancer with cellular immunotherapy (dCellVax), modulating key molecular processes in cancer stem cell through its patented molecular targeting approaches (BORIS), and repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate).

AREAS OF INTEREST

Hematopoiesis (Blood formation)
Breast Cancer
Liver Cancer
Leukemia
Myelodysplastic Syndrome
Aplastic Anemia

CLINICAL TRIALS

https://www.regenbiopharmainc.com/products.html

HemaXellerate

Aplastic Anemia Stem Cell Therapy – HemaXellerate – IND #15376 CLEARED TO PROCEED TO PHASE I / II CLINICAL TRIALS


dCellVax 

Breast Cancer – dCellVax - IND #16200
CellVax is a dendritic cell based immunotherapy that stimulates the patient’s immune system through a process called “gene silencing.”


DiffronC

Myelodysplastic Syndrome Gene Silencing – DiffronC
DiffronC is a novel form of therapy called differentiation therapy that is expected to have much milder toxicity than chemotherapy. The mechanism of action is to correct the specific genes that prevent the myelodysplastic syndrome stem cell from producing mature blood cells.


Filings This Year:

Received On: Period Ending:
10-Q 08/05/2021 06/30/2020
10-Q08/05/2021 03/31/2020
10-Q08/05/2021 12/31/2019
10-K08/04/2021 09/30/2020
8-K07/14/2021 07/08/2021
8-K07/13/2021 07/13/2021
8-K07/02/2021 06/16/2021
8-K06/30/2021 06/28/2021
8-K06/28/2021 06/28/2021


The price ran up to .0819 on Monday, April 12th 2021 with a few factors in mind...

#1 Licensing deals; 2 in particular related to cancer research, from which they will receive a percentage of profits in the form of Royalties etc...

#2 50K Cash + 50 thousand shares of Oncology Pharma Inc which at the time were valued close to 2 million U.S dollars

#3 24 Patents owned by Regen

#4 FOMO Buying based upon Countless OTC Tickers running on news IE ENZ!C TSN!P DPL$ GGI! ALP!P etc etc... what can you say, when the express train leaves, it doesn't make pit stops...

Dpl$ ran above 5 Cents in February, retraced immediately, stayed below 2 cents for 3 months and then made a rapid leap past 5 cents and touched .2020.... They have no revenue and no signed contracts to date...

RGBP has
- 2 signed deals
- booked revenues with money in the bank and more to come
- a CEO with wealth in millions which is public knowledge
- and 24 patents!


RECENTLY PUBLISHED ARTICLES:

August 7th 2021 - Insider Financial

https://insiderfinancial.com/4-penny-stocks-to-keep-an-eye-on-tsoi-rgbp-vitx-asti/181899/


August 5th 2021 - Top News Guide

https://topnewsguide.com/2021/08/05/regen-biopharma-otcmktsrgbp-stock-is-in-news-what-to-expect-now/

July 30th 2021 - Microcap Daily

https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-biotech-sleeper-sitting-on-a-major-league-patent-portfolio/132392/

July 2nd 2021 - Microcap Daily

https://microcapdaily.com/regen-biopharma-inc-otcmkts-rgbp-major-runner-as-biotech-secures-valuable-nr2f6-cancer-t-cell-activation-patent/132063/

Getting Ready For A Monster-Run, Undoubtedly!